AgingResearch.NewsJoin free

Unity Biotechnology

CompanyUnited StatesFounded 2009

Wikidata

Unity Biotechnology develops 2 assets, the furthest in phase 2 (UBX0101 in knee osteoarthritis). Mostly small molecule acting on cellular senescence, apoptosis and MDM2; based in the United States, founded in 2009.

2
Assets
Furthest stage
Phase 2
Raised
US$206.3m
1
Trial
1
Signal

Pipeline

2

  • UBX0101

    Senolytic MDM2/p53 interaction inhibitor that induces apoptosis in senescent cells

    Phase 2, Small molecule, Apoptosis, MDM2, knee osteoarthritis

  • foselutoclax

    Senolytic BCL-xL inhibitor given into the eye to clear senescent cells from diseased retinal vessels

    Discontinued, Small molecule, Cellular senescence, BCL2L1

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms6
  • Trials1
  • Funding rounds and grants2
  • Signals3
  • Similar companies6

Papers

Intelligence